Quratis Inc.

Quratis develops vaccines in South Korea. It is involved in developing QTP101, a vaccine for tuberculosis. Its portfolio also includes QTP104, a next-generation mRNA vaccine, CPP (Cell Penetrating Peptide) Platform, a cell and bacterial penetration peptide drug delivery platform technology, and Peptide Nucleic Acid (PNA), a synthetic analogue of DNA in which the deoxyribose phosphate backbone Drugs contract development and manufacturing services. Quratis Inc. was incorporated in 2016 and is based in Cheongju-si, South Korea.